Clinical Trial

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-17; most recent amendment 2025-07-02.
Trial Details
NCT Number NCT06843044
Lead Sponsor Valenta Pharm JSC
Conditions Anxiety, Neurasthenia, Adjustment Disorders
Enrollment 250 participants
Start Date 2025-01-13
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-08